Search PubMed⌕ Search

Biomedical subjects

M Guslandi

Publications and source records attributed to M Guslandi.

At least 127 records · Page 7Linked to original sources
PubMed1984

Lack of effect of domperidone on gastrin release: evidence for a peripheral activity of the drug.

The effect of intravenous administration of domperidone, a dopamine receptor antagonist with peripheral activity, on basal and submaximal pentagastrin-stimulated gastric acid secretion and gastrin release has been evaluated in healthy volunteers. No significant changes were observed in the parameters studied. The lack of effect on gastrin release appears to confirm that domperidone is unable to penetrate the blood brain barrier in appreciable amounts in adults.

Adult↗
PubMed1983

Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis.

45 patients with symptomatic reflux esophagitis were randomly treated with either Ranitidine (150 mg b.i.d.) or Metoclopramide (10 mg t.i.d.) for six weeks. The severity of dyspeptic symptoms and the grade of endoscopic and histological esophagitis were assessed before and after treatment. Both drugs proved significantly effective in inducing symptomatic and endoscopic improvement, but Ranitidine appeared significantly superior in promoting disappearance or improvement of endoscopic esophagitis. Moreover Ranitidine was found to significantly reduce the severity of histological changes, whereas Metoclopramide was unable to do so.

Adult↗
PubMed1982

Gastric potential difference: a reliable index of mucosal integrity?

The clinical significance and the diagnostic value of measurement of gastric potential difference are critically reviewed. The lack of correlation between behaviour of potential difference and state of the mucosal barrier, especially under the influence of agents inducing changes in gastric acid secretion, are discussed.

Biological Transport, Active↗
PubMed1982

Do cytoprotective prostaglandins act as mild irritants?

Of the various mechanisms proposed to explain the cytoprotective properties of prostaglandins, mucus discharge seems the most probable. Mild irritants capable of eliciting mucus release have also been shown to exert cytoprotection. It is suggested that prostaglandins act as mild irritants of the mucosa and that cytoprotection is a mucosal reaction to mild irritation, through stimulation of mucus discharge.

Adenylyl Cyclases↗
PubMed1981

Effect of loperamide and naloxone on gastric acid secretion in healthy man.

The effect of acute oral administration of three different doses (4, 8, and 16 mg) of loperamide, a peripheral opiate agonist, on basal and submaximal pentagastrin-stimulated gastric acid secretion was evaluated in healthy volunteers. Both basal and stimulated gastric secretion were significantly lowered by 8 and 16 mg of the drug in comparison with a control study, while 4 mg was ineffective. Naloxone, a specific opiate antagonist, decreased slightly but not significantly both basal and pentagastrin-stimulated gastric acid secretion, when infused intravenously at the rate of 30 micrograms/kg/h, but completely abolished the inhibitory effect of loperamide on gastric acidity. These data also suggest that opiates may be involved in the regulation of gastric acid secretion in man by acting at a peripheral site, as loperamide does not cross the blood-brain barrier.

Adult↗
PubMed1981

Tolmetin sodium in clinical practice: a survey of 32,207 treated patients.

A total of 32,207 patients with various rheumatic disorders were treated with the non-steroidal antiphlogistic tolmetin in the course of a post-marketing survey performed in Italy with the co-operation of 4,205 general practitioners. The treatment proved effective in about 90% of patients treated. The tolerability of the drug was excellent or good in 91% of cases. Side-effects involving mostly the gastro-intestinal tract occurred in 12.3% of cases, but treatment was discontinued in only 3.6% of patients. The results confirm the remarkable therapeutic activity and the good tolerability of tolmetin sodium.

Adolescent↗
PubMed1980

Carbenoxolone maintenance in cimetidine-healed patients.

The effects of 3 months' maintenance treatments with cimetidine, 400 mg at bedtime, or with carbenoxolone, 150 mg/daily, in patients whose duodenal ulcers healed after an initial course with cimetidine were compared. Carbenoxolone promoted a significant enhancement of cimetidine-altered mucus secretion, whereas in the cimetidine group no mucus recovery was found. Within 6 months from healing time 48.1% of the patients in the cimetidine group relapsed, compared with 21.4% in the carbenoxolone group. The difference is statistically significant (p < 0.05). Our results suggest that carbenoxolone maintenance is more effective than cimetidine in preventing recurrence of ulcers, being also a cheaper and shorter maintenance treatment.

Adult↗
PubMed1980

Effect of carbenoxolone and cimetidine on gastric mucin.

To determine whether the addition of carbenoxolone to a cimetidine regimen would prevent mucus deficiency in patients with duodenal ulcer, we compared the effect of combined therapy with the effects of treatment with cimetidine alone and carbenoxolone alone. Carbenoxolone proved to be ineffective on gastric mucus induced by cimetidine, the behavior of gastric mucin fractions being similar to that observed in patients treated with cimetidine alone. When used alone, however, carbenoxolone demonstrated mucus-stimulating action.

Adult↗